Chuan Chen

Dr. Chuan Chen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Neurotherapeutics
Verified
Journal Article
Open access
JSJun Sun
Jun Sun
QZQiuhua Zeng
Qiuhua Zeng
ZWZhimin Wu
Zhimin Wu
LHLixin Huang
Lixin Huang
TSTao Sun
Tao Sun
MZMinghua Zhong
Minghua Zhong
Berberine (BBR) has demonstrated potent anti-inflammatory effects by modulating macrophage polarization. Nevertheless, the precise mechanisms through which berberine regulates post-injury inflammation within the peripheral nerve system remain elusive. This study seeks to elucidate the role of BBR and its underlying mechanisms in inflammation following peripheral nerve injury (PNI). Adult male C57BL/6J mice subjected to PNI were administered daily doses of berberine (0, 60, 120, 180, 240 ​mg/kg) via gavage from day 1 through day 28. Evaluation of the sciatic function index (SFI) and paw withdrawal threshold revealed that BBR dose-dependently enhanced both motor and sensory functions. Immunofluorescent staining for anti-myelin basic protein (anti-MBP) and anti-neurofilament-200 (anti-NF-200), along with histological staining comprising hematoxylin-eosin (HE), luxol fast blue (LFB), and Masson staining, demonstrated that BBR dose-dependently promoted structural regeneration. Molecular analyses including qRT-PCR, Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence confirmed that inactivation of the NLRP3 inflammasome by MCC950 shifted macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, while also impeding macrophage infiltration. Furthermore, BBR significantly downregulated the expression of the NLRP3 inflammasome and its associated molecules in macrophages, thereby mitigating NLRP3 inflammasome activation-induced macrophage M1 polarization and inflammation. In summary, BBR's neuroprotective effects were concomitant with the suppression of inflammation after PNI, achieved through the inhibition of NLRP3 inflammasome activation-induced macrophage M1 polarization.

6 December 2022 in Experimental Neurology
Verified
Journal Article
Closed access
JSJun Sun
Jun Sun
ZLZhi Liao
Zhi Liao
ZLZhangyu Li
Zhangyu Li
HLHao Li
Hao Li
ZWZhimin Wu
Zhimin Wu
MZMinghua Zhong
Minghua Zhong

24 May 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
JSJun Sun
Jun Sun
QZQiuhua Zeng
Qiuhua Zeng
ZWZhimin Wu
Zhimin Wu
ZLZhangyu Li
Zhangyu Li
QGQun Gao
Qun Gao
BZBaoyu Zhang
Baoyu Zhang
Background: Endothelial cell (EC)-driven intraneural revascularization (INRV) and Schwann cells-derived exosomes (SCs-Exos) both play crucial roles in peripheral nerve injury (PNI). However, the interplay between them remains unclear. We aimed to elucidate the effects and underlying mechanisms of SCs-Exos on INRV following PNI. Results: We found that GW4869 inhibited INRV, as well as that normoxic SCs-Exos (N-SCs-Exos) exhibited significant pro-INRV effects in vivo and in vitro that were potentiated by hypoxic SCs-Exos (H-SCs-Exos). Upregulation of glycolysis emerged as a pivotal factor for INRV after PNI, as evidenced by the observation that 3PO administration, a glycolytic inhibitor, inhibited the INRV process in vivo and in vitro. H-SCs-Exos more significantly enhanced extracellular acidification rate/oxygen consumption rate ratio, lactate production, and glycolytic gene expression while simultaneously suppressing acetyl-CoA production and pyruvate dehydrogenase E1 subunit alpha (PDH-E1α) expression than N-SCs-Exos both in vivo and in vitro. Furthermore, we determined that H-SCs-Exos were more enriched with miR-21-5p than N-SCs-Exos. Knockdown of miR-21-5p significantly attenuated the pro-glycolysis and pro-INRV effects of H-SCs-Exos. Mechanistically, miR-21-5p orchestrated EC metabolism in favor of glycolysis by targeting von Hippel-Lindau/hypoxia-inducible factor-1α and PDH-E1α, thereby enhancing hypoxia-inducible factor-1α-mediated glycolysis and inhibiting PDH-E1α-mediated oxidative phosphorylation. Conclusion: This study unveiled a novel intrinsic mechanism of pro-INRV after PNI, providing a promising therapeutic target for post-injury peripheral nerve regeneration and repair. Graphical

1 July 2019 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LZLian-Hua Zhao
Lian-Hua Zhao
CCChuan Chen
Chuan Chen
CMCheng-Yi Mao
Cheng-Yi Mao
HXHe Xiao
He Xiao
PFPing Fu
Ping Fu
GWGe Wang
Ge Wang

6 February 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
NMNi Mo
Ni Mo
CTChuyang Tai
Chuyang Tai
YYYang Yang
Yang Yang
CLCong Ling
Cong Ling
BZBaoyu Zhang
Baoyu Zhang
CCChuan Chen
Chuan Chen
Approximately half of patients with chronic ischemic cerebrovascular disease (CICD) exhibit poor revascularization. Metallothionein 2 A (MT2A) has a high affinity for metal ions and is potentially capable of chelating toxic copper ions to alleviate the impairment of angiogenesis. Therefore, we hypothesized that MT2A could promote angiogenesis in chronically ischemic brains by neutralizing excessive copper ions during copper overload (CPO). We first collected dura matter (DM) samples from CICD patients and examined the expression of cuproptosis-related genes (DLAT, FDX1, and SDHB) to confirm the inhibitory effect of CPO on angiogenesis. Then, we treated human umbilical vein endothelial cells (HUVECs) with different concentrations of elesclomol and CuCl2 to determine the optimal concentration for inducing CPO. HUVEC activity and mitochondrial structure and function were detected to explore the ability of MT2A to alleviate CPO-induced damage. Finally, a rat model of 2-vessel occlusion plus encephalo-myo-synangiosis (2VO + EMS) with CPO was established to test the proangiogenic effect of MT2A through the copper–mitochondria regulatory mechanism in chronically ischemic brains. Compared with those from Matsushima grade A patients, DM samples from Matsushima grade C patients presented significantly greater DLAT and FDX1 expression and significantly lower SDHB expression. The optimal drug concentration for inducing CPO was subsequently determined, and in vitro experiments revealed that HUVEC activity was significantly decreased in the CPO group under hypoxic culture, accompanied by increased DLAT oligomerization, decreased SDHB expression, increased HSP70 expression. Moreover, significantly more common mitochondrial aberrations and significantly lower mitochondrial activity were detected in the CPO group compare with the control group. Additionally, MT2A overexpression alleviated CPO-induced mitochondrial dysfunction and cytotoxicity, improving HUVEC viability. In vivo, a CPO rat model was established, and CPO inhibited cerebral angiogenesis in 2VO + EMS model rats. Moreover, significantly greater CD31 expression, less DLAT accumulation, more mitochondria, and fewer mitochondrial abnormalities were observed in the CPOMT2A+ group than in the CPO group, accompanied by significantly improved cerebral blood perfusion and cognitive function. MT2A can promote angiogenesis in chronically ischemic brains by neutralizing excessive copper ions and rescuing CPO-induced mitochondrial dysfunction.

3 November 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MGMingying Geng
Mingying Geng
YSYang Song
Yang Song
HXHe Xiao
He Xiao
ZWZhiyu Wu
Zhiyu Wu
XDXiaojuan Deng
Xiaojuan Deng
GWGe Wang
Ge Wang
The diagnostic and prognostic evaluation of primary central nervous system lymphoma (PCNSL) is challenging due to the lack of sensitive biomarkers. The present study aimed to evaluate the value of interleukin (IL)‑10 in this context. Between October 2016 and December 2018, 91 patients with suspected intracranial neoplasms were recruited, and the concentrations of IL‑10 or IL‑6 in both the cerebrospinal fluid (CSF) and blood were measured and analyzed by the Kruskal‑Wallis test. The correlation between CSF IL‑6 or IL‑10 levels and tumor size was determined by Spearman's coefficient analysis. The receiver operating characteristic curve was used to evaluate the diagnostic value of CSF IL‑6 and IL‑10 levels. Median progression‑free survival (PFS) and overall survival time were calculated using Kaplan‑Meier survival analysis. Among the 91 patients, 3 were diagnosed with PCNSL on the basis of neuroimaging data and CSF IL‑10 levels. A total of 35 cases were verified to show diffuse large B‑cell lymphoma on histological assessment, 17 of which were diagnosed as PCNSL by MRI. The median PFS and OS were 8.00 months [95% confidence interval (CI), 3.94‑12.06) and 17.5 months (95% CI, 11.55‑23.45) respectively in the 12 PNCSL cases with regular follow up. The diagnostic efficiency of serum IL‑6 levels was lower than that of serum IL‑10 levels (P=0.030), which, in turn, was lower than that of CSF IL‑10 levels (P<0.001). The decline and increase in CSF IL‑10 levels was concurrent with improvement and deterioration in manifestation, respectively, which predated the MRI variation. High CSF IL‑10 levels indicated low Karnofsky performance scale scores and shortened PFS times. CSF IL‑10 levels higher than 1,000 pg/ml signified disease progression. CSF IL‑10 levels could be a sensitive biomarker guiding the differential diagnosis, early recurrence detection, prognostic evaluation and therapeutic strategy establishment in cases of PCNSL.